Genzyme, a Sanofi company (SNY: Quote), and Isis Pharmaceuticals Inc. (ISIS: Quote), announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a negative opinion for its marketing authorization application for KYNAMROTM for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Genzyme plans to request a re-examination of the CHMP Opinion.
An application for KYNAMRO is currently under review by the U.S. FDA.
Click here to receive FREE breaking news email alerts for Genzyme Corp. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org